On this edition of “Ask Dr. J”, Dr. Russell Jaffe is asked if the PERQUE Detox Program is recommended before or after taking the LRA Test. Tune in to hear what Dr. J has to say!
On this edition of “Ask Dr. J”, Dr. Russell Jaffe is asked if he has noticed any trends in the LRA results for food and chemical sensitivities in reference demographics – such as age, gender, race, ethnicity, geographic? Tune in to hear what Dr. J has to say!
On this edition of “Ask Dr. J”, Dr. Russell Jaffe is asked if he has ever considered offering sublingual immuno-therapy as a conjunctive therapy for the ELISA/ACT allergen panel. Tune in to hear what Dr. J has to say!
On this edition of “Ask Dr. J”, a practitioner writes in to ask Dr. Rusell Jaffe if it is possible to reduce or even reverse activity of certain autoimmune disorders by using the LRA Test by ELISA/ACT combined with PERQUE Nutraceuticals. Tune in to hear what Dr. J has to say!
On this episode of “Ask Dr. J”, Dr. Russell Jaffe is asked if a person that suffers primarily from digestive symptoms should do an LRA Food Panel Test, or if they should combine that with a chemical panel as well. Tune in to hear what Dr. J has to say!
On this episode of “Ask Dr. J”, someone writes in to ask Dr. Russell Jaffe to talk about RAST IgE Skin testing and how it compares to the LRA test by ELISA/ACT. Tune in to hear what Dr. J has to say!
In this week’s edition of “Ask Dr. J”, Dr. Russell Jaffe is asked, “Does increased gut permeability mean higher reactivity on the LRA Test?”
On this episode of “Ask Dr. J.”, Dr. Jaffe is asked how the LRA Test by ELISA/ACT compares to the silicon-based biochip method. See what Dr. J has to say!
We read with interest a recent web post comparing and contrasting various methods of detecting food and chemical sensitivities. We applaud the effort to provide an in-depth review of what can be a confusing subject. With regard to the technical aspects of the LRA by ELISA/ACT® testing, we would like to clarify a few details here so patients, practitioners and readers are well informed about this procedure and its clinical significance.
In the description of the LRA testing method the writer states, “the assumption is that this increase in volume is caused by the activation of the major histocompatibility complex (MHC) of the white blood cell, which triggers an immune response. However, there is no research provided to support this assumption.”
It is important to understand that the LRA does NOT use change in lymphocyte volume as its measurement index. The methods that use devices to detect such changes have high variance on split sample comparisons and have limited clinical value. We would also point out that it is NOT the MHC complex, per se, that is activated. The mechanism for Lymphocyte Response Assay (LRA) has been known for some time, although we are the first to make it clinically reproducible. When a lymphocyte is presented with an antigen to which it was previously sensitized a series of kinase induced phosphorylation occurs. There are several results including that the glycocalyx becomes phosphorylated and as a result the highly charged glycoproteins push away from each other. This creates the halo of light seen to reflect cell activation. Phosphorylated signals induce nuclear cell division and proliferation. (1)
There are 3 types of delayed reactions (2). B Lymphocytes are directly responsible for Type 2 and 3 reactions; T cells are responsible for type 4 non-antibody reactions. Type 2 delayed reactions that are antibody based are also associated with lymphocytes since B type of lymphocytes produce the Immunoglobulins involved. Therefore, only a functional test like LRA measures types 2, 3, and 4 concurrently and directly.
LRA cell cultures are reproducible with a variance of less than 3% for over 30 years on consecutive blind split samples – consecutive data shown in Table 1 presented at the American Society for Investigative Pathology (ASIP) conference in 2016 (3).
Table 1. Consecutive blind split Lymphocyte Response Assay (LRA) samples showing high split sample reproducibility.
|# items matched||# items unmatched||(%) items matched||(%) items unmatched||Time (years)|
Test precision is measured best by consecutive blind split samples analyzed over at least 2 years as shown in this table. By contrast other cell culture methods that assess lymphocytic white blood cell function, report 15-30% variance. LRA by this method is a documented advance in precision, sensitivity, specificity and predictive significance.
A different post lists as a weakness of LRA testing that it does not look at granulocytes and therefore does not measure Type I reactions. In Type I reactions histamine sensitizes neutrophils (type of granulocyte) which are responsible for the Type I or IgE (immediate) allergic reaction. (4) The post is correct that the LRA does not measure these reactions because they are totally different in mechanism compared to delayed reactions. There are many types of white blood cells involved in immune reactions beyond lymphocyte and granulocyte subsets. Because lymphocytes are the key cells involved in all 3 types of delayed reactions, the LRA testing is devoted to lymphocytes.
In evaluating the studies of LRA testing, the writer presented the use of supplements and a support group in the fibromyalgia study as “horribly confounding.” This study was designed to be comprehensive and it achieved meaningful results as noted in the journal (5). This study showed more improvement over six months than any previous comprehensive intervention. A single variable study would have been entirely inappropriate in such a community based multi-variable experiment.
The community-based outcome studies in diabetes and fibromyalgia show documented substantially better outcomes using the results of the LRA testing compared to best standard of care (5,6). There is more clinical and basic research in support of LRA than any other functional immunology tests. More studies are always needed. In the meantime, LRA tests lead in both technology and clinical application. We encourage you to dive deeper into any of the technical aspects of LRA testing, I invite you to contact us to schedule a conversation.
Russell Jaffe, MD, Ph.D., CCN
- Peter J. Delves, Seamus J. Martin, Dennis R. Burton, Ivan M. Roitt. 13thEd Roitt’s Essential Immunology
- Brostoff J, Challacombe SJ, Food Allergy and Intolerance. Saunders Ltd.; 2ndedition(2002)
- Lynch A E, Jaffe R Lymphocyte Response Assay: Report on Precision of a Novel Cell Culture Test2016, The FASEB Journal:4. https://www.fasebj.org/doi/abs/10.1096/fasebj.30.1_supplement.51.4#t1-514
- Lynch A E, Jaffe R, “Lymphocyte Response Assay: Report on Precision of Novel Cell Culture Test, Experimental Biology,” ASIP, San Diego, CA, 2016.
- Alcañiz L,Vega A, Chacón P, El Bekay R, Ventura I, Aroca R, Blanca M, Bergstralh DT, Monteseirin J.Histamine production by human neutrophils. FASEB J. 2013 Jul;27(7):2902-2910.
- Deuster PA and Jaffe R. A Novel Treatment for fibromyalgia improves Clinical Outcomes in a Community Based Study.J Musculo Pain 1998; 6:133-149.
- Jaffe R, Mani J, DeVane J, Mani H. Tolerance loss in diabetics: Association with foreign antigen exposure. Diabetic Medicine: J British Diabetic Association2006Aug; 23(8): 924-925.
On this episode of “Ask Dr. J.”, Dr. Russell Jaffe is asked why a patient would have new sensitivities after taking the LRA Test and avoiding the items for 3-6 months.
On this week’s edition of “Ask Dr. J”, Dr. Russell Jaffe weighs in on practitioners making their own extra …
We now understand that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein …